|
시장보고서
상품코드
1863874
족부백선(무좀) 치료 시장 : 약제 클래스별, 투여 경로별, 제제별, 처방 유형별, 연령층별, 감염 유형별, 유통경로별, 최종사용자별, 지역별Tinea Pedis Treatment Market, By Drug Class, By Route of Administration, By Formulation, By Prescription Type, By Age Group, By Infection Type, By Distribution Channel, By End User, By Geography |
||||||
족부백선(무좀) 치료 시장은 2025년에 15억 4,000만 달러로 추정되고, 2032년까지 26억 2,000만 달러에 이를 것으로 예측되며, 2025-2032년 CAGR7.9%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2024년 | 2025년 시장 규모 : | 15억 4,000만 달러 |
| 실적 데이터 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간(2025-2032년) CAGR : | 7.90% | 2032년 가치 예측 : | 26억 2,000만 달러 |
세계 무좀 치료 시장은 전 세계 수백만 명에게 영향을 미치는 가장 흔한 곰팡이 감염 질환 중 하나인 무좀을 치료하는 피부 치료제 산업에서 중요한 부분을 차지하고 있습니다. 무좀은 주로 적색모낭균(Trichophyton rubrum), 석고상모낭균(Trichophyton mentagrophytes), 면상표피사상균(Epidermophyton floccosum)과 같은 피부사상균에 의해 발생하는 표재성 진균 감염입니다. 성진균 감염입니다.
이 질환은 발, 특히 손가락 사이에 발생하며 가려움증, 작열감, 비늘과 같은 증상부터 물집, 이차적인 세균 감염과 같은 심각한 증상까지 유발할 수 있습니다. 치료 상황으로는 테르비나핀, 클로트리마졸, 미코나졸 등의 외용 항진균제 외에 중증 및 재발 환자를 위한 전신 투여 약제 등 다양한 치료법이 사용되고 있습니다. 시장의 성장 궤적은 발 위생에 대한 인식 증가, 라이프스타일 변화에 따른 곰팡이 감염 발생률 증가, 스포츠 활동 참여 증가, 신흥 경제국의 의료 접근성 확대 등의 요인에 의해 영향을 받고 있습니다. 의료진은 유효성, 안전성, 환자 순응도를 우선시하는 증거 기반 치료 프로토콜에 의존하고 있으며, 치료 기간은 일반적으로 감염의 중증도 및 선택한 치료 접근법에 따라 2주에서 6주까지 다양합니다.
시장 역학
세계 무좀 치료 시장은 여러 가지 강력한 촉진요인에 의해 주도되고 있으며, 이러한 요인들이 복합적으로 작용하여 다양한 지역에서의 성장 전망을 강화하고 있습니다. 주요 성장 요인은 스포츠 및 피트니스 활동 참여 증가, 공공시설의 공동 이용을 촉진하는 도시화, 곰팡이 증식에 적합한 환경을 조성하는 생활방식의 변화로 인한 전 세계적인 무좀 감염의 확산에 기인합니다. 의료비 지출 증가와 진단 능력의 향상으로 조기 발견 및 조기 치료가 가능해졌고, 발 건강 및 위생에 대한 인식 확대는 전문적인 의료 개입을 원하는 환자들의 행동을 촉진하고 있습니다. 면역기능 저하 및 동반질환으로 인해 곰팡이 감염에 취약한 고령 인구 증가도 시장 수요를 더욱 확대시키고 있습니다.
그러나 시장에는 심각한 제약도 존재합니다. 환자가 자가 치료를 선호하는 일반의약품의 선택이 다양해짐에 따라 전문적인 치료가 지연되고, 처방약의 매출이 감소할 수 있습니다. 치료 기간이 길어지거나 무증상 감염으로 인한 치료 비순응도 또한 지속적인 시장 성장에 대한 추가적인 도전이 되고 있습니다. 항진균제 승인에 대한 규제 강화와 약제 내성 균주의 출현은 새로운 치료법을 개발하려는 제약사들에게 장벽이 되고 있습니다. 한편, 환자의 복약 순응도와 치료 결과를 향상시킬 수 있는 네일 래커, 서방형 제제, 병용요법 등 혁신적인 약물 전달체 개발에는 큰 기회가 존재합니다. 특히 아시아태평양과 라틴아메리카 등 신흥 시장의 미개발 잠재력은 의료 인프라 개선, 가처분 소득 증가, 사람들의 건강 의식 향상에 힘입어 수익성 높은 확장 기회를 가져다 줄 수 있습니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR%)을 제시하는 세계 무좀 치료 시장에 대한 상세한 분석을 제공합니다.
- 또한, 각 부문의 잠재적 수익기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 이 보고서는 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들이 채택하고 있는 경쟁 전략에 대한 중요한 통찰력도 제공합니다.
- 이 보고서에서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 무좀 치료 시장의 주요 기업 프로파일을 제공합니다.
- 이 보고서는 마케팅 담당자 및 기업 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있도록 돕습니다.
- 이 보고서는 세계 무좀 치료제 시장의 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 무좀 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 전망
- 보고서 설명
- 시장 정의와 범위
- 주요 요약
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 시나리오
- 제품 발매 및 승인
- PEST 분석
- PORTER 분석
- 인수합병(M&A) 시나리오
- 업계 동향
제4장 세계의 족부백선(무좀) 치료 시장, 약제 클래스별, 2020년-2032년
- 아릴아민 및 벤질아민(예 : terbinafine, naftifine 등)
- 아졸계 약제(예 : clotrimazole, miconazole 등)
- 히드록시피리돈(예 : ciclopirox)
- 모르폴린(예 : amorolfine)
- 기타(예 : tolnaftate, undecylenic acid)
제5장 세계의 족부백선(무좀) 치료 시장, 투여 경로별, 2020년-2032년
- 외용
- 경구
제6장 세계의 족부백선(무좀) 치료 시장, 제제별, 2020년-2032년
- 크림 및 연고
- 스프레이
- 분말
- 겔
- 정제
- 캡슐
- 용액제
제7장 세계의 족부백선(무좀) 치료 시장, 처방전 유형별, 2020년-2032년
- 시판약(OTC)
- 처방전(Rx)
제8장 세계의 족부백선(무좀) 치료 시장, 연령층별, 2020년-2032년
- 소아
- 성인
- 고령자
제9장 세계의 족부백선(무좀) 치료 시장, 감염 유형별, 2020년-2032년
- Interdigital
- Moccasin (chronic hyperkeratotic)
- 수포성
- 궤양성
제10장 세계의 족부백선(무좀) 치료 시장, 유통경로별, 2020년-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제11장 세계의 족부백선(무좀) 치료 시장, 최종사용자별, 2020년-2032년
- 병원
- 피부과 클리닉
- 가정치료 환경
- 외래 및 1차의료(Primary care)
제12장 세계의 족부백선(무좀) 치료 시장, 지역별, 2020년-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동
- 아프리카
- 남아프리카
- 북아프리카
- 중앙아프리카
제13장 경쟁 구도
- Bayer AG
- Novartis AG
- Sandoz Group
- Teva Pharmaceutical Industries Ltd
- Viatris Inc
- Sun Pharmaceutical Industries Ltd
- Taro Pharmaceutical Industries Ltd
- Galderma SA
- Bausch Health Companies Inc
- Perrigo Company plc
- Dr Reddy's Laboratories Ltd
- Glenmark Pharmaceuticals Ltd
- Cipla Ltd
- Zydus Lifesciences Ltd
- Sanofi Consumer Healthcare
제14장 애널리스트 추천 사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제15장 참고 문헌과 조사 방법
- 참고 문헌
- 조사 방법
- 출판사에 대해
Tinea Pedis Treatment Market is estimated to be valued at USD 1.54 Bn in 2025 and is expected to reach USD 2.62 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 1.54 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.90% | 2032 Value Projection: | USD 2.62 Bn |
The global tinea pedis treatment market represents a significant segment within the dermatological therapeutics industry, addressing one of the most prevalent fungal infections affecting millions worldwide. Tinea pedis, commonly known as athlete's foot, is a superficial fungal infection caused primarily by dermatophytes including Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum.
This condition affects the skin of the feet, particularly between the toes, causing symptoms ranging from itching, burning, and scaling to more severe manifestations including blisters and secondary bacterial infections. The treatment landscape encompasses various therapeutic modalities including topical antifungals such as terbinafine, clotrimazole, and miconazole, as well as systemic medications for severe or recurrent cases. The market's growth trajectory is influenced by factors including increasing awareness of foot hygiene, rising incidence of fungal infections due to lifestyle changes, growing participation in sports activities, and expanding healthcare access in emerging economies. Healthcare providers rely on evidence-based treatment protocols that prioritize efficacy, safety, and patient compliance, with treatment duration typically ranging from two to six weeks depending on infection severity and chosen therapeutic approach.
Market Dynamics
The global tinea pedis treatment market is propelled by several robust drivers that collectively strengthen its growth prospects across diverse geographical regions. The primary growth driver stems from the escalating global prevalence of tinea pedis infections, attributed to increased participation in sports and fitness activities, urbanization leading to shared public facilities usage, and lifestyle modifications that create favorable conditions for fungal proliferation. Rising healthcare expenditure and improved diagnostic capabilities enable earlier detection and treatment initiation, while growing awareness campaigns about foot health and hygiene drive patient seeking behavior for professional medical intervention. The expanding geriatric population, who demonstrate higher susceptibility to fungal infections due to compromised immune systems and comorbidities, further amplifies the market demand.
However, the market faces significant restraints including the availability of over-the-counter alternatives that patients often prefer for self-medication, potentially delaying professional treatment and reducing prescription medication sales. Treatment non-compliance due to lengthy therapeutic regimens and the asymptomatic nature of mild infections pose additional challenges to sustained market growth. Regulatory stringency regarding antifungal drug approvals and the emergence of drug-resistant fungal strains create barriers for pharmaceutical companies developing new therapeutic solutions. Conversely, substantial opportunities exist in the development of innovative drug delivery systems including nail lacquers, sustained-release formulations, and combination therapies that enhance patient compliance and treatment outcomes. The untapped potential in emerging markets, particularly in Asia Pacific and Latin America, presents lucrative expansion opportunities driven by improving healthcare infrastructure, rising disposable incomes, and increasing health consciousness among populations.
Key Features of the Study
- This report provides in-depth analysis of the global tinea pedis treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tinea pedis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bayer AG, Novartis AG, Sandoz Group, Teva Pharmaceutical Industries Ltd, Viatris Inc, Sun Pharmaceutical Industries Ltd, Taro Pharmaceutical Industries Ltd, Galderma SA, Bausch Health Companies Inc, Perrigo Company plc, Dr Reddy's Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Cipla Ltd, Zydus Lifesciences Ltd, and Sanofi Consumer Healthcare
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tinea pedis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tinea pedis treatment market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Allylamines and Benzylamines (e.g., terbinafine, naftifine, etc.)
- Azoles (e.g., clotrimazole, miconazole, etc.)
- Hydroxypyridones (e.g., ciclopirox)
- Morpholines (e.g., amorolfine)
- Others (e.g., tolnaftate, undecylenic acid)
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Topical
- Oral
- Formulation Insights (Revenue, USD Bn, 2020 - 2032)
- Creams and Ointments
- Sprays
- Powders
- Gels
- Tablets
- Capsules
- Solution
- Prescription Type Insights (Revenue, USD Bn, 2020 - 2032)
- Over-the-counter (OTC)
- Prescription (Rx)
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Infection Type Insights (Revenue, USD Bn, 2020 - 2032)
- Interdigital
- Moccasin (chronic hyperkeratotic)
- Vesiculobullous
- Ulcerative
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Dermatology Clinics
- Homecare Settings
- Outpatient/Primary care
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Bayer AG
- Novartis AG
- Sandoz Group
- Teva Pharmaceutical Industries Ltd
- Viatris Inc
- Sun Pharmaceutical Industries Ltd
- Taro Pharmaceutical Industries Ltd
- Galderma SA
- Bausch Health Companies Inc
- Perrigo Company plc
- Dr Reddy's Laboratories Ltd
- Glenmark Pharmaceuticals Ltd
- Cipla Ltd
- Zydus Lifesciences Ltd
- Sanofi Consumer Healthcare
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Tinea Pedis Treatment Market, By Drug Class
- Global Tinea Pedis Treatment Market, By Route of Administration
- Global Tinea Pedis Treatment Market, By Formulation
- Global Tinea Pedis Treatment Market, By Prescription Type
- Global Tinea Pedis Treatment Market, By Age Group
- Global Tinea Pedis Treatment Market, By Infection Type
- Global Tinea Pedis Treatment Market, By Distribution Channel
- Global Tinea Pedis Treatment Market, By End User
- Global Tinea Pedis Treatment Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Tinea Pedis Treatment Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Allylamines and Benzylamines (e.g., terbinafine, naftifine, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Azoles (e.g., clotrimazole, miconazole, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hydroxypyridones (e.g., ciclopirox)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Morpholines (e.g., amorolfine)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others (e.g., tolnaftate, undecylenic acid)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Tinea Pedis Treatment Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Topical
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Tinea Pedis Treatment Market, By Formulation, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Creams and Ointments
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sprays
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Powders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Gels
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Solution
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Tinea Pedis Treatment Market, By Prescription Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Over-the-counter (OTC)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Prescription (Rx)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Tinea Pedis Treatment Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn
9. Global Tinea Pedis Treatment Market, By Infection Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Interdigital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Moccasin (chronic hyperkeratotic)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Vesiculobullous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Ulcerative
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Tinea Pedis Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Tinea Pedis Treatment Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Dermatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Outpatient/Primary care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Tinea Pedis Treatment Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Prescription Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Infection Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz Group
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Taro Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Galderma SA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bausch Health Companies Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Perrigo Company plc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Dr Reddy's Laboratories Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Zydus Lifesciences Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi Consumer Healthcare
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About Us
